Polen Capital released its Q4 investor letter for the Polen 5Perspectives Small Growth Strategy, showing a return of -1.3% gross and -1.5% net of fees, compared to the Russell 2000 Growth Index’s 1.2% return. Small caps saw a 1.2% return in 4Q, with Biotech standing out as a major performer. The Strategy nearly doubled its Biotech exposure in 4Q due to rising interest rates and AI tailwinds. The Strategy changed its name to Polen 5Perspectives Small Growth to highlight its 5 viewpoints framework.

Corcept Therapeutics Incorporated (NASDAQ:CORT) was highlighted in Polen’s Q4 investor letter. The pharmaceutical company focuses on developing medications for severe disorders, with a stock price of $35.34 per share on Feb 23, 2026. Corcept’s one-month return was -22.56%, and shares lost 42.82% over the past 52 weeks, with a market cap of $3.724 billion. The company is at an inflection point with promising Phase 3 data for relacorilant in adrenal cancer and other indications.

Corcept Therapeutics Incorporated (NASDAQ:CORT) is a biopharmaceutical company focusing on cortisol activity modulation. The stock faced pressure in Q4 due to concerns about slower Korlym sales growth and pipeline approval uncertainty. 39 hedge fund portfolios held Corcept at the end of Q4, up from 28 in the previous quarter. While Corcept has potential, certain AI stocks may offer greater upside potential and lower downside risk.

In another article, Corcept Therapeutics Incorporated (NASDAQ:CORT) was covered, along with a list of biotechnology stocks with over 50% upside potential. For more investor letters from hedge funds and leading investors, visit the hedge fund investor letters Q4 2025 page. Check out The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money for further insights.

Read more at Yahoo Finance: Is Corcept Therapeutics Incorporated (CORT) at an inflection point?